Clinical Trials Logo

Esophageal Adenocarcinoma clinical trials

View clinical trials related to Esophageal Adenocarcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05394740 Active, not recruiting - Clinical trials for Gastric Adenocarcinoma

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Start date: June 6, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-arm, single-center Phase Ib/II study to exploratorily evaluate the tolerability, safety, and efficacy of regorafenib and nivolumab plus chemotherapy in patients with unresectable advanced/recurrent gastric/ gastroesophageal junction/esophageal adenocarcinoma.

NCT ID: NCT04929392 Active, not recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Start date: January 25, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery in treating patients with esophageal or esophageal/gastroesophageal junction cancer that has not spread to other places in the body (non-metastatic). Pembrolizumab is an immunotherapy drug that works by harnessing the immune system to attack cancer. Lenvatinib is an anti-cancer drug that works by stopping or slowing down the growth of cancer cells. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery may kill more tumor cells.

NCT ID: NCT04554771 Active, not recruiting - Clinical trials for Esophageal Adenocarcinoma

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

BASALT
Start date: January 27, 2021
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to demonstrate that stroma-targeting by tocilizumab in patients with adenocarcinoma of the esophagus or gastroesophageal junction with highly activated stroma increases efficacy of chemoradiotherapy measured by pathological response according to the Mandard criteria. Patients will be grouped for ADAM12, a non-invasive blood-borne marker of stromal activation.

NCT ID: NCT04499924 Active, not recruiting - Clinical trials for Gastric Adenocarcinoma

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

MOUNTAINEER-02
Start date: March 22, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer). This study will also look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer. Study treatment will be given in 28-day cycles. In the Phase 2 part of the trial, participants and their doctors will know what drugs are being given (open-label). In the Phase 3 part, the study is "blinded." This means that participants, their doctor, and the study sponsor will not know which drugs are being given.

NCT ID: NCT04159974 Active, not recruiting - Clinical trials for Esophageal Adenocarcinoma

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

RICE
Start date: September 30, 2019
Phase: Phase 2
Study type: Interventional

A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition

NCT ID: NCT03539822 Active, not recruiting - Colorectal Cancer Clinical Trials

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

CAMILLA
Start date: October 22, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment with biologic agents like cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at safety, tolerability and efficacy endpoints.

NCT ID: NCT03429816 Active, not recruiting - Clinical trials for Gastric Adenocarcinoma

OPPOSITE: Outcome Prediction Of Systemic Treatment in Esophagogastric Carcinoma

OPPOSITE
Start date: April 15, 2018
Phase: N/A
Study type: Interventional

Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen. - Aim 1: Organoid cultures of pre-treatment tumor biopsies will be established and exposed to the same chemotherapy as the corresponding patient; in vitro response to treatment will be correlated with the in vivo response of patients. - Aim 2: Whole genome, methylome and RNA sequencing of tumors biopsies and organoids will be performed prior to as well as after systemic treatment. Histological and clinical outcome will be correlated with molecular subtypes.

NCT ID: NCT02998268 Active, not recruiting - Clinical trials for Esophageal Adenocarcinoma

Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma

Start date: March 7, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, multicenter phase II study of pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of pembrolizumab with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma as assessed by 1 year disease free survival rate.

NCT ID: NCT02872116 Active, not recruiting - Gastric Cancer Clinical Trials

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

CheckMate649
Start date: October 12, 2016
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.

NCT ID: NCT00964080 Active, not recruiting - Clinical trials for Gastric Adenocarcinoma

Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma

Start date: May 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric, gastro-esophageal junction or esophageal adenocarcinoma.